|Videos|May 25, 2023
The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment
Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
FDA Grants Priority Review to Zanubrutinib Regimen in Frontline MCL
4
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
5